Biohaven Pharmaceuticals, Inc.

Clinical trials sponsored by Biohaven Pharmaceuticals, Inc., explained in plain language.

Biohaven Pharmaceuticals, Inc. BHVN NYSE

A biopharmaceutical company focused on neuroscience and immunology.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Trials to join now! 1 Not yet finished but already full! 2 Completed 4 Terminated 1

New hope for SCA patients: expanded access to investigational drug troriluzole

Disease control Expanded access

This expanded access program offers the investigational drug troriluzole to people with spinocerebellar ataxia (SCA), a rare brain disorder that affects movement and coordination. Participants take a daily pill. The goal is to provide access to the drug while it is still being st…

Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Disease control

Last updated Jun 27, 2026 08:09 UTC

Biohaven Pharmaceuticals, Inc.

New hope for SCA patients: expanded access to investigational drug troriluzole